Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
February 2013 Vol 6, No 1, Special Issue
Leukemia
Initial Choice of TKI in Patients with CML Probably Not Important
Mark Knight
Read More
Drug Updates
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
Lynne Lederman, PhD
Read More
Payers' Perspectives
New Data Presented at Highlight Challenges and Opportunities for Payers
Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Multiple Myeloma
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
Read More
Multiple Myeloma
Four-Drug Induction and 2-Drug Maintenance Boost Overall Survival in Patients with Newly Diagnosed Myeloma
Audrey Andrews
Read More
Multiple Myeloma
Host Factors Important in Patients with Myeloma
Caroline Helwick
Read More
Multiple Myeloma
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
Read More
Leukemia
Evidence Lacking for Eliminating Prophylactic Platelet Transfusions
Audrey Andrews
Read More
Lymphoma
Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas
Caroline Helwick
Read More
Lymphoma
PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes
Wayne Kuznar
Read More
1
2
3
Page 1 of 3
Results 1 - 10 of 30